CARDIOVASCULAR DRUGS MARKET ANALYSIS
For instance, in December 2017, Medicure Inc. — a Canada-based pharmaceutical company — through its subsidiary Medicure International Inc., acquired exclusive license for 7 years to market and sell cardiovascular drug for the treatment of primary hyperlipidemia or mixed dyslipidemia in the U.S and its territories. In October 2017, the Sun Pharmaceutical Industries’ subsidiary in the U.S received approval from the U.S Food and Drug Administration (FDA) to sell generic version of its Coreg CR. Coreg CR is used to treat various heart conditions including high blood pressure and heart failure. In August 2017, Takeda Pharmaceutical Company Limited and Cardurion Pharmaceuticals entered into partnership to develop next generation products for the treatment of cardiovascular diseases and heart failure.
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India : 
